Tricuspid regurgitation is a public health crisis.


Journal

Progress in cardiovascular diseases
ISSN: 1873-1740
Titre abrégé: Prog Cardiovasc Dis
Pays: United States
ID NLM: 0376442

Informations de publication

Date de publication:
Historique:
received: 23 10 2019
accepted: 23 10 2019
pubmed: 11 11 2019
medline: 10 3 2020
entrez: 11 11 2019
Statut: ppublish

Résumé

Tricuspid regurgitation (TR) has long been a forgotten valve disease of benign reputation. However, TR deserves higher attention and represents a growing public health crisis. Indeed, recent epidemiological data suggest that 1.6 million US residents are affected by moderate or severe TR. Furthermore, large recent cohorts demonstrate that higher degrees of TR are associated with considerable excess mortality, independent of all background clinical and hemodynamic contexts. Finally, analysis of recent cohorts also shows that >90% of patients with moderate or severe TR are never offered surgical treatment and remain untreated. Therefore, TR is frequent, severely impacts outcomes, and is rarely treated, justifying the development of new strategies and methods for its treatment.

Identifiants

pubmed: 31707061
pii: S0033-0620(19)30134-3
doi: 10.1016/j.pcad.2019.10.009
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

447-451

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Maurice Enriquez-Sarano (M)

Cardiovascular Department, University of Ottawa, Canada; Cardiovascular Department, University of Tel-Aviv, Israel; Cardiovascular Department, University of Amiens, France. Electronic address: sarano.maurice@gmail.com.

David Messika-Zeitoun (D)

Cardiovascular Department, University of Ottawa, Canada; Cardiovascular Department, University of Tel-Aviv, Israel; Cardiovascular Department, University of Amiens, France.

Yan Topilsky (Y)

Cardiovascular Department, University of Ottawa, Canada; Cardiovascular Department, University of Tel-Aviv, Israel; Cardiovascular Department, University of Amiens, France.

Christophe Tribouilloy (C)

Cardiovascular Department, University of Ottawa, Canada; Cardiovascular Department, University of Tel-Aviv, Israel; Cardiovascular Department, University of Amiens, France.

Giovanni Benfari (G)

Cardiovascular Department, University of Ottawa, Canada; Cardiovascular Department, University of Tel-Aviv, Israel; Cardiovascular Department, University of Amiens, France.

Hector Michelena (H)

Cardiovascular Department, University of Ottawa, Canada; Cardiovascular Department, University of Tel-Aviv, Israel; Cardiovascular Department, University of Amiens, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH